RET C611F
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C611F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
32846061
detail...
|
RET C620F
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C609R
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
32846061
detail...
|
RET C618F
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C634Y
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET fusion
|
thyroid cancer
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate of 79% (15/19), including one complete and 14 partial responses, with a median response duration of 18.4 months, and median progression-free survival of 20.1 months in adult and pediatric patients 12 years and older with RET fusion-positive thyroid cancer who were previously treated (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C620S
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C630Y
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C618G
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C630F
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET V804M
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
Case Reports/Case Series |
Actionable |
In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in an objective response in three patients (3/5) and stable disease in two patients (2/5) with medullary thyroid cancer harboring RET V804M or RET V804L who were previously treated (PMID: 32846061; NCT03157128).
|
detail...
32846061
|
RET C609Y
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C634W
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634W; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET V804L
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
Case Reports/Case Series |
Actionable |
In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in an objective response in three patients (3/5) and stable disease in two patients (2/5) with medullary thyroid cancer harboring RET V804L or RET V804M who had been treated previously (PMID: 32846061; NCT03157128).
|
32846061
|
RET C630R
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
32846061
detail...
|
RET C630G
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C611R
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C611R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C620W
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620W; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET mutant
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - Has Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55), with five complete and 33 partial responses, in adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations who were previously treated, while patients who had not been previously treated demonstrated an ORR of 73% (64/88), with ten complete and 54 partial responses (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C609S
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
32846061
detail...
|
RET C634F
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C611G
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C611G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET D898_E901del
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET D898_E901del; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C611Y
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C611Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
32846061
detail...
|
RET A883F
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET A883F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C634R
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
32846061
detail...
|
RET C620R
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET D631_L633delinsE
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET D631_L633delinsE; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET M918T
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET M918T; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C618Y
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C609F
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C611S
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C611S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C634S
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C618R
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618R; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C634L
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634L; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C620G
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C634G
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C618W
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618W; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
32846061
detail...
|
RET E623_L633del
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET E623_L633del; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C620Y
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C620Y; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
detail...
32846061
|
RET C609W
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609W; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C630S
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C630S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
detail...
32846061
detail...
|
RET C618S
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C618S; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|
RET C609G
|
medullary thyroid carcinoma
|
sensitive
|
Selpercatinib
|
FDA approved - On Companion Diagnostic |
Actionable |
In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C609G; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128).
|
32846061
detail...
detail...
|